NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
Clinical Trials
6 trialsNCT04056910 2025-02-27
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
University of Pittsburgh
Phase 2 Completed
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed
NCT04730349 2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02526017 2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT02529072 2020-03-26
AVERT
Duke University
Phase 1 Completed